Pharmacokinetics and Safety of Armodafinil in Chinese Healthy Humans After Multiple‐Dose Oral Administration
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Liwei Lang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing, Beijing, China. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Modafinil, Wakefulness-Promoting Agents. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Armodafinil, the R‐enantiomer of modafinil that promotes wakefulness, was studied regarding its pharmacokinetics and safety in healthy Chinese subjects after multiple‐dose oral administration (200 mg daily for 7 days). Twelve subjects participated in this single‐center, self‐contrast study. The plasma concentrations of armodafinil and its metabolites (R‐modafinil acid and modafinil sulfone) were measured by ultra‐performance liquid chromatography–tandem mass spectrometry, and drug safety was evaluated during the study. The steady‐state accumulation ratio of armodafinil was 1.5, and its metabolites also accumulated with ratios of 1.3 and 7.8, respectively. Although the mean steady‐state half‐life was similar to that after a single dose, the area under the concentration–time curve, maximum plasma concentration, and clearance of armodafinil changed significantly after multiple dosing. The drug was safe with no serious adverse events, yet fever occurred in 6 subjects, which was not reported before. Modafinil sulfone had significant accumulation, implying the need for further study on its central nervous system–activating properties in Chinese patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing, Beijing, China.
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing, China.
- Clinical Trial Research Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Zitieren
APA
Lang, L., Dong, Y., Zhu, Z., Zhu, S., Wang, H., Bi, J., & Wang, F. (2025). Pharmacokinetics and Safety of Armodafinil in Chinese Healthy Humans After Multiple‐Dose Oral Administration. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1527
Vancouver
Lang L, Dong Y, Zhu Z, Zhu S, Wang H, Bi J, et al. Pharmacokinetics and Safety of Armodafinil in Chinese Healthy Humans After Multiple‐Dose Oral Administration. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1527
BibTeX
@article{Lang2025,
author = {Lang, Liwei and Dong, Yuan and Zhu, Zhenzhen and Zhu, Shanwei and Wang, Hongyan and Bi, Jingfeng and Wang, Fang},
title = {Pharmacokinetics and Safety of Armodafinil in Chinese Healthy Humans After Multiple‐Dose Oral Administration},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1527}
}
EUVIMED